Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) Stock Competitors & Peer Comparison

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, RPRX has a market cap of 27.2B. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while RPRX trades at $61.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas RPRX's P/E ratio is 11.68. In terms of profitability, KNSA's ROE is +0.14%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, KNSA is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check RPRX's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, CORT has a market cap of 13.1B. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while CORT trades at $122.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas CORT's P/E ratio is 345.86. In terms of profitability, KNSA's ROE is +0.14%, compared to CORT's ROE of +0.08%. Regarding short-term risk, KNSA is more volatile compared to CORT. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check CORT's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas WBA's P/E ratio is -1.64. In terms of profitability, KNSA's ROE is +0.14%, compared to WBA's ROE of -0.42%. Regarding short-term risk, KNSA is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check WBA's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, LQDA has a market cap of 6.1B. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while LQDA trades at $68.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas LQDA's P/E ratio is 490.14. In terms of profitability, KNSA's ROE is +0.14%, compared to LQDA's ROE of +1.50%. Regarding short-term risk, KNSA is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check LQDA's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, PBH has a market cap of 2.4B. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while PBH trades at $51.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas PBH's P/E ratio is 11.61. In terms of profitability, KNSA's ROE is +0.14%, compared to PBH's ROE of +0.09%. Regarding short-term risk, KNSA is less volatile compared to PBH. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check PBH's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas HROWL's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, KNSA is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check HROWL's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, LTGO has a market cap of 1.3B. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while LTGO trades at $22.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas LTGO's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to LTGO's ROE of N/A. Regarding short-term risk, KNSA is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check LTGO's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas HROWM's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, KNSA is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check HROWM's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, HELP has a market cap of 780.4M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while HELP trades at $12.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas HELP's P/E ratio is -3.02. In terms of profitability, KNSA's ROE is +0.14%, compared to HELP's ROE of -0.71%. Regarding short-term risk, KNSA is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check HELP's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while SVA trades at $6.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas SVA's P/E ratio is -5.68. In terms of profitability, KNSA's ROE is +0.14%, compared to SVA's ROE of -0.01%. Regarding short-term risk, KNSA is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check SVA's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, CUVL has a market cap of 390.3M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while CUVL trades at $7.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas CUVL's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to CUVL's ROE of N/A. Regarding short-term risk, KNSA is more volatile compared to CUVL. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check CUVL's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, HITI has a market cap of 215.3M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while HITI trades at $2.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas HITI's P/E ratio is 61.25. In terms of profitability, KNSA's ROE is +0.14%, compared to HITI's ROE of -0.43%. Regarding short-term risk, KNSA is less volatile compared to HITI. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check HITI's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, CELG-RI has a market cap of 208.4M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while CELG-RI trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, KNSA is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CELG-RI's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while ATLN trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas ATLN's P/E ratio is -0.68. In terms of profitability, KNSA's ROE is +0.14%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, KNSA is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check ATLN's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, CTOR has a market cap of 70.6M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while CTOR trades at $0.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas CTOR's P/E ratio is -1.62. In terms of profitability, KNSA's ROE is +0.14%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, KNSA is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CTOR's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, SDEV has a market cap of 57M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while SDEV trades at $1.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas SDEV's P/E ratio is -0.20. In terms of profitability, KNSA's ROE is +0.14%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, KNSA is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check SDEV's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas RAD's P/E ratio is -0.05. In terms of profitability, KNSA's ROE is +0.14%, compared to RAD's ROE of +2.76%. Regarding short-term risk, KNSA is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check RAD's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while GLTO trades at $21.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas GLTO's P/E ratio is -1.78. In terms of profitability, KNSA's ROE is +0.14%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, KNSA is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check GLTO's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, NSRX has a market cap of 34.5M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while NSRX trades at $4.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas NSRX's P/E ratio is -5.56. In terms of profitability, KNSA's ROE is +0.14%, compared to NSRX's ROE of +0.00%. Regarding short-term risk, KNSA is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check NSRX's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, SCYX has a market cap of 32.1M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while SCYX trades at $5.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas SCYX's P/E ratio is -1.49. In terms of profitability, KNSA's ROE is +0.14%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, KNSA is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check SCYX's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, CNSY has a market cap of 20.6M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while CNSY trades at $3.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas CNSY's P/E ratio is -0.42. In terms of profitability, KNSA's ROE is +0.14%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, KNSA is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CNSY's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, BFRI has a market cap of 18.9M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while BFRI trades at $1.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas BFRI's P/E ratio is -2.69. In terms of profitability, KNSA's ROE is +0.14%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, KNSA is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check BFRI's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, BFRIW has a market cap of 16.7M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while BFRIW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, KNSA's ROE is +0.14%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, KNSA is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check BFRIW's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, COSM has a market cap of 11.6M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while COSM trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas COSM's P/E ratio is -0.29. In terms of profitability, KNSA's ROE is +0.14%, compared to COSM's ROE of -1.19%. Regarding short-term risk, KNSA is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check COSM's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas CJJD's P/E ratio is -0.46. In terms of profitability, KNSA's ROE is +0.14%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, KNSA is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CJJD's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas SSY's P/E ratio is -2.86. In terms of profitability, KNSA's ROE is +0.14%, compared to SSY's ROE of -0.09%. Regarding short-term risk, KNSA is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check SSY's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, POM has a market cap of 6.5M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while POM trades at $0.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas POM's P/E ratio is -0.19. In terms of profitability, KNSA's ROE is +0.14%, compared to POM's ROE of +0.16%. Regarding short-term risk, KNSA is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check POM's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, BGMS has a market cap of 4.9M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while BGMS trades at $0.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas BGMS's P/E ratio is -0.25. In terms of profitability, KNSA's ROE is +0.14%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, KNSA is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check BGMS's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, PAVS has a market cap of 4.3M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while PAVS trades at $5.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas PAVS's P/E ratio is -0.06. In terms of profitability, KNSA's ROE is +0.14%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, KNSA is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check PAVS's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas MDVL's P/E ratio is -0.05. In terms of profitability, KNSA's ROE is +0.14%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, KNSA is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check MDVL's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas ATNFW's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, KNSA is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check ATNFW's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, KNSA's ROE is +0.14%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, KNSA is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check BGMSP's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas AZNH's P/E ratio is 38.35. In terms of profitability, KNSA's ROE is +0.14%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, KNSA is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check AZNH's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, PRPH has a market cap of 346.2K. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while PRPH trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas PRPH's P/E ratio is -0.01. In terms of profitability, KNSA's ROE is +0.14%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, KNSA is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check PRPH's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, KNSA's ROE is +0.14%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, KNSA is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check LFLYW's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas ESRX's P/E ratio is 10.69. In terms of profitability, KNSA's ROE is +0.14%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, KNSA is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check ESRX's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, CPD has a market cap of 0. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas CPD's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to CPD's ROE of N/A. Regarding short-term risk, KNSA is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check CPD's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, OREX has a market cap of 0. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas OREX's P/E ratio is -0.14. In terms of profitability, KNSA's ROE is +0.14%, compared to OREX's ROE of -0.54%. Regarding short-term risk, KNSA is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check OREX's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas IPXL's P/E ratio is -10.11. In terms of profitability, KNSA's ROE is +0.14%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, KNSA is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check IPXL's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, POZN has a market cap of 0. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas POZN's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to POZN's ROE of +0.61%. Regarding short-term risk, KNSA is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check POZN's competition here

Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KNSA stands at 6B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, KNSA is priced at $79.03 on the NASDAQ, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KNSA currently has a P/E ratio of 87.81, whereas SHPG's P/E ratio is 11.35. In terms of profitability, KNSA's ROE is +0.14%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, KNSA is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check SHPG's competition here